s227928
Chronic Myelomonocytic Leukemia (CMML)
Servier Bio-Innovation LLCPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
97 Active assets in the Chronic Myelomonocytic Leukemia (CMML) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pevonedistat Takeda | Phase 3 | BB |
Venetoclax Servier Bio-Innovation LLC | Phase 2/3 | BB |
Azacitidine The University of Hong Kong | Phase 3 | BB |
Astx727 Taiho Oncology, Inc. | Phase 3 | BB |
Idarubicine Fred Hutchinson Cancer Center | Phase 3 | BB |
View all 50 →
Same molecule, other indications
s227928 is also rated in:
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
NR
Indicative ·
/ 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →